BEAM vs. NTLA, KYMR, DNA, VCEL, SANA, FUSN, DNLI, RXRX, CGON, and NMRA
Should you be buying Beam Therapeutics stock or one of its competitors? The main competitors of Beam Therapeutics include Intellia Therapeutics (NTLA), Kymera Therapeutics (KYMR), Ginkgo Bioworks (DNA), Vericel (VCEL), Sana Biotechnology (SANA), Fusion Pharmaceuticals (FUSN), Denali Therapeutics (DNLI), Recursion Pharmaceuticals (RXRX), CG Oncology (CGON), and Neumora Therapeutics (NMRA). These companies are all part of the "medical" sector.
Beam Therapeutics (NASDAQ:BEAM) and Intellia Therapeutics (NASDAQ:NTLA) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends, community ranking and analyst recommendations.
Beam Therapeutics has a net margin of -35.09% compared to Intellia Therapeutics' net margin of -893.34%. Beam Therapeutics' return on equity of -15.90% beat Intellia Therapeutics' return on equity.
In the previous week, Beam Therapeutics had 2 more articles in the media than Intellia Therapeutics. MarketBeat recorded 8 mentions for Beam Therapeutics and 6 mentions for Intellia Therapeutics. Beam Therapeutics' average media sentiment score of 0.18 beat Intellia Therapeutics' score of 0.14 indicating that Beam Therapeutics is being referred to more favorably in the media.
Beam Therapeutics has higher revenue and earnings than Intellia Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.
Intellia Therapeutics received 378 more outperform votes than Beam Therapeutics when rated by MarketBeat users. Likewise, 69.55% of users gave Intellia Therapeutics an outperform vote while only 51.28% of users gave Beam Therapeutics an outperform vote.
Beam Therapeutics presently has a consensus target price of $41.00, indicating a potential upside of 89.81%. Intellia Therapeutics has a consensus target price of $67.00, indicating a potential upside of 234.67%. Given Intellia Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Intellia Therapeutics is more favorable than Beam Therapeutics.
Beam Therapeutics has a beta of 1.77, meaning that its share price is 77% more volatile than the S&P 500. Comparatively, Intellia Therapeutics has a beta of 1.77, meaning that its share price is 77% more volatile than the S&P 500.
99.7% of Beam Therapeutics shares are owned by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are owned by institutional investors. 4.4% of Beam Therapeutics shares are owned by company insiders. Comparatively, 3.0% of Intellia Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Beam Therapeutics beats Intellia Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Beam Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BEAM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BEAM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Beam Therapeutics Competitors List
Related Companies and Tools
